Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone for Target Organ Damage in Resistant Hypertension
NCT00138944Phase 3Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Jan 2007
- Primary completion
- May 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of eplerenone in resistant hypertension (RH), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started Jan 2007; status: completed.
02
Drugs
eplerenone
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT00138944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138944.